US 12,077,544 B2
Irreversible inhibitors of menin-MLL interaction
Thomas Butler, Redwood City, CA (US); Jim Palmer, Warrandyte (AU); Ravi Upasani, San Jose, CA (US); Matthew Welsch, New Haven, CT (US); Sridhar Vempati, Edison, NJ (US); Brendan Kelly, Castlecomer (IE); and Edward Painter, Chappaqua, NY (US)
Assigned to Biomea Fusion, Inc., Redwood City, CA (US)
Filed by BIOMEA FUSION, INC., Redwood City, CA (US)
Filed on Jan. 9, 2023, as Appl. No. 18/094,929.
Application 18/094,929 is a division of application No. 17/352,146, filed on Jun. 18, 2021, granted, now 11,702,421.
Application 17/352,146 is a continuation of application No. 16/732,226, filed on Dec. 31, 2019, granted, now 11,084,825, issued on Aug. 10, 2021.
Claims priority of provisional application 62/786,842, filed on Dec. 31, 2018.
Prior Publication US 2023/0227458 A1, Jul. 20, 2023
Int. Cl. C07D 401/14 (2006.01); C07D 401/04 (2006.01); C07D 401/06 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01)
CPC C07D 487/04 (2013.01) [C07D 401/04 (2013.01); C07D 401/06 (2013.01)] 20 Claims
 
1. A compound selected from the group consisting of:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
or a salt thereof.